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Abstract
The additive Hemicell®-L is a liquid preparation of endo-1,4-b-mannanase that is authorised as a
zootechnical feed additive for chickens for fattening. The applicant has requested the renewal of the
authorisation, new uses and the modiﬁcation of the manufacturing process including the change of the
production strain. The new production strain is a genetically modiﬁed strain of Paenibacillus lentus
obtained from a strain that has been evaluated previously by EFSA and considered to be safe. The
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) evaluated the
genetic modiﬁcation and concluded that the sequences introduced to obtain the production strain did
not raise safety concerns. The production strain and its DNA were not detected in the additive. The
Panel concluded that the additive is safe for chickens for fattening and turkeys for fattening at the
recommended level. These conclusions were extended or extrapolated to the other target species
under application. The Panel concluded that the results obtained in the toxicological studies performed
with the fermentation products of the recipient strain and of another genetically modiﬁed strain
obtained from the same recipient strain could support the safety for the consumer of the product
obtained with the new production strain. The additive is not a dermal or eye irritant and it is not a
dermal sensitiser. However, considering that the active substance is a protein, the additive should be
regarded as a potential sensitiser. The Panel concluded that the additive has a potential to be
efﬁcacious as a zootechnical additive for the target species at 79,200 U/kg.
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Summary
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on the safety and
efﬁcacy of Hemicell®-L (endo-1,4-b-mannanase) as a feed additive for chickens and turkeys for
fattening, chickens reared for laying, turkeys reared for breeding and minor poultry species for
growing or raised for laying/breeding.
The additive Hemicell®-L is a liquid preparation of endo-1,4-b-mannanase (Enzyme Commission
number: 3.2.1.78) that is authorised as a zootechnical feed additive for chickens for fattening. The
applicant has requested the renewal of the authorisation, new uses (chickens reared for laying turkeys
and minor poultry species) and the modiﬁcation of the manufacturing process including the change of
the production strain. The new production strain is a genetically modiﬁed strain of Paenibacillus lentus
which has been developed from a strain that has been evaluated previously by the European Food
Safety Authority (EFSA) and considered to be safe. The genetic modiﬁcation was fully described and
the sequences introduced to obtain the production strain did not raise safety concerns. The production
strain and its DNA were not detected in the additive.
Based on the tolerance trials evaluated, the FEEDAP Panel concluded that the additive is safe for
chickens for fattening and turkeys for fattening at the recommended level. These conclusions were
extended to chickens reared for laying and turkeys reared for breeding. Considering the margin of
safety the Panel also extrapolated the conclusion from those studies to minor poultry species for
growing or raised for laying/breeding purposes.
Toxicological tests performed with the fermentation product obtained with the new production
strain were not made available. However, the applicant submitted two sets of toxicological studies,
including genotoxicity and subchronic oral toxicity studies, performed with the fermentation product
obtained from the recipient strain or from a genetically modiﬁed strain obtained from the same
recipient strain. These tests had already been assessed by EFSA in previous assessments. The results
of the tests did not indicate a toxicological concern from any of the fermentation products. The
Panel evaluated the suitability of those data to support the safety of the product obtained from the
new production strain. The Panel concluded that the results obtained in the toxicological studies
performed with the fermentation products of the recipient strain and of another genetically modiﬁed
strain obtained from the same recipient strain could support the safety for the consumer of the
product obtained with the new production strain. The additive under assessment was therefore
considered safe for consumers of food products obtained from the new production strain.
The additive is not a dermal or eye irritant and it is not a dermal sensitiser. However, considering
that the active substance is a protein, the additive should be regarded as a potential sensitiser.
The efﬁcacy of the additive for chickens for fattening has been evaluated in a previous opinion. In
that evaluation, four studies were assessed in which the additive used was the previous formulation of
the additive obtained with the previous production strain. The results of the four studies showed a
signiﬁcant improvement of body weight gain in four trials and on the feed to gain ratio at the
recommended level (79,200 U/kg feed). The use of the previous formulation of the additive still
allowed a conclusion for the additive under evaluation because
the differences in the composition of the additive are not expected to have an impact
on the efﬁcacy of the enzyme. Four studies in turkeys for fattening were provided, only one performed
with the enzyme produced with the new strain. The results of four long-term trials would allow a
conclusion at 100,000 U/kg feed; however, considering the data on the chickens for fattening,
the Panel concluded that the additive has a potential to be efﬁcacious in turkeys for fattening at
79,200 U/kg feed. The results from the efﬁcacy trials in chickens were extended to chickens raised for
laying and to turkeys reared for breeding purposes. Since the mode of action of enzymes is well
known and can reasonably be expected to be the same among poultry species. Therefore, the
Panel considers that the conclusions reached in chickens for fattening can be extrapolated to all minor
poultry species for growing or reared for laying/breeding purposes.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7. Article 13(3) of that Regulation lays down that if the holder of
an authorisation proposes changing the terms of the authorisation by submitting an application to the
Commission, accompanied by the relevant data supporting the request for the change, the Authority
shall transmit its opinion on the proposal to the Commission and the Member States. Moreover, Article
14(1) of that Regulation lays down that an application for renewal shall be sent to the Commission at
the latest one year before the expiry date of the authorisation.
The European Commission received two request from Eli Lilly and Company Ltd2 for authorisation/
re-evaluation/renewal of the authorisation of the product Hemicell®-L (endo-1,4-b-mannanase), when
used as a feed additive for chickens for fattening or reared for laying, turkeys for fattening or reared
for breeding and minor poultry species (category: zootechnical additive; functional group: digestibility
enhancers).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive), under Article 13(3) (modiﬁcation of
the authorisation of a feed additive), and under Article 14(1) (renewal of the authorisation). EFSA
received directly from the applicant the technical dossiers in support of this application. The particulars
and documents in support of the application were considered valid by EFSA as of 14 April 2016.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Hemicell®-L (endo-1,4-b-mannanase), when used under the proposed conditions of use (see
Section 3.1.5).
1.2. Additional information
The additive Hemicell®-L is a liquid preparation of endo-1,4-b-mannanase (Enzyme Commission
number: 3.2.1.78) that is authorised as a feed additive for chickens for fattening.3 This authorisation is
given to the enzyme produced by a non-genetically modiﬁed strain of Bacillus lentus deposited with
the accession number ATCC 55045.
The Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) adopted an
opinion on the safety and efﬁcacy of Hemicell®-L as a feed additive for chickens for fattening (EFSA,
2006).
The applicant has requested the renewal of the authorisation and new uses (chickens reared for
laying turkeys and minor poultry species), the applicant also requests for a modiﬁcation of the
manufacturing process including the change of the production strain.
2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of two technical
dossiers4 in support of the authorisation request for the use of Hemicell®-L as a feed additive. The
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Eli Lilly and Company Ltd, Priestley Road, RG24 9 NL Basingstoke, UK.
3 Commission Regulation (EC) No 786/2007 of 4 July 2007 concerning the authorisation of endo-1,4-b-mannanase EC 3.2.1.78
(Hemicell) as a feed additive OJ L, 5.7.2007, p. 8.
4 FEED dossier reference: FAD-2015-0042 and FAD-2015-0047.
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technical dossiers were prepared following the provisions of Article 7 of Regulation (EC) No 1831/2003,
Regulation (EC) No 429/20085 and the applicable EFSA guidance documents.
The European Union Reference Laboratory (EURL) considered that the conclusions and
recommendations reached in the previous assessment are valid and applicable for the current
application.6
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Hemicell®-L is
in line with the principles laid down in Regulation (EC) No 429/2008 and the relevant guidance
documents: Guidance on zootechnical additives (EFSA FEEDAP Panel, 2012a), Technical guidance:
Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical Guidance for
assessing the safety of feed additives for the environment (EFSA, 2008a), Guidance on the renewal of
the authorisation of feed additives (EFSA FEEDAP Panel, 2013), Guidance for establishing the safety
of additives for the consumer (EFSA FEEDAP Panel, 2012b), Guidance on studies concerning the safety
of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c), Technical Guidance: Microbial
Studies (EFSA, 2008b), Technical Guidance: Extrapolation of data from major species to minor species
regarding the assessment of additives for use in animal nutrition (EFSA, 2008c), Guidance on the
assessment of bacterial susceptibility to antimicrobials of human and veterinary importance (EFSA
FEEDAP Panel, 2012d), Guidance on the risk assessment of genetically modiﬁed microorganisms and
their products intended for food and feed use (EFSA GMO Panel, 2011) and Guidance on the
assessment of the efﬁcacy of feed additives (EFSA FEEDAP Panel, 2018).
3. Assessment
This opinion deals with the assessment of the safety and efﬁcacy of Hemicell®-L (endo-1,4-b-
mannanase (mannanase); Enzyme Commission number 3.2.1.78) as a feed additive for chickens for
fattening or reared for laying, turkeys for fattening or reared for breeding and minor poultry species.
3.1. Characterisation
3.1.1. Characterisation of active substance
The authorisation of the mannanase was given to the mannanase produced by Bacillus lentus ATCC
55045. In the current application, the applicant has requested to modify the manufacturing process,
including the change of the production strain. The new strain is a genetically modiﬁed strain derived
from the previous production strain, currently identiﬁed as Paenibacillus lentus, which is deposited at
the German Collection of Microorganisms and Cell Cultures (DSMZ) with the accession number DSM
32052.7
3.1.1.1. Characterisation of the genetically modiﬁed production strain
Characteristics of the recipient or parental microorganism
Characteristics of the donor organisms
5 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC)
No 1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications
and the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
6 The full report is available on the EURL website: https://ec.europa.eu/jrc/en/eurl/feed-additives/evaluation-reports/fad-2011-
0049?search&form-return.
7 Technical dossier/Section II/Annex II.2.1.2.2.
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Description of the genetic modiﬁcation process
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3.1.2. Manufacturing process
3.1.3. Characterisation of the additive
Hemicell®-L is a liquid additive; the composition of which additive has been modiﬁed with respect
to that previously evaluated, . The previous formulation
included the enzyme concentrate, sorbitol, monosodium glutamate, sodium chloride and calcium
chloride. The new formulation of the additive contains (w/w) the enzyme product (10–30%) sorbitol
(30–40%), sodium chloride (6–10%), monosodium glutamate (2–6%), calcium chloride (< 1%),
sodium acetate (< 1%), caramel colour (< 1%), potassium sorbate (< 1%), added water (10–50%).13
This formulation ensures a minimum of 7.2 9 105 Units14 per mL. The study of the batch-to-batch
variation in ﬁve batches showed a mean value of 10.7 9 105 Units with a coefﬁcient of variation (CV)
of 2.8%. The product has a viscosity of 11.0 centipoises at 20°C, surface tension of 53 dynes/cm,15 a
pH of 7.2 and a speciﬁc gravity of 1.23 g/mL.16
Three batches of Hemicell®-L were analysed for chemical and microbiological contamination.17
The analyses of chemical contamination included arsenic (< 0.5 mg/kg), cadmium (< 0.25 mg/kg),
lead (< 0.05 mg/kg), mercury (< 0.1 mg/kg), ﬂuoride (< 15 mg/kg), antimony (< 0.5 mg/kg),
bismuth (< 1.0 mg/kg), copper (< 0.5 mg/kg), molybdenum (< 0.5 mg/kg), silver (< 0.5 mg/kg) and
tin (< 0.5 mg/kg). Polychlorinated dibenzo-p-dioxins (PCDD) and polychlorinated dibenzofurans (PCDF)
were analysed in three batches and were < 0.29 WHO-PCDD-TEQ ng/kg, and < 0.18 WHO-PCDF-TEQ
ng/kg, respectively. Analytical data were provided for the following mycotoxins: aﬂatoxins B1, B2, G1
and G2 (individual < 1 lg/kg), zearalenone (< 25 lg/kg), ochratoxin A (< 1.1 lg/kg), deoxynivalenol
(< 0.5 mg/kg), fumonisins (sum of fumonisin B1 and B2 < 1.0 mg/kg) and T2-toxin (< 25 lg/kg).
No viable cells or DNA of the production strain were found in the liquid
intermediate, since this is a more concentrated product than the additive, the results apply to the
additive.
14 One Unit of mannanase activity is deﬁned as the amount of enzyme that generates 0.72 microgram of reducing sugars from a
mannan-containing substrate (locust bean gum) per minute at pH 7.5 and 40°C.
15 Technical dossier/Section II/Annex II.1.5.1.
16 Technical dossier/Supplementary information December 2017/Annex II.2.2.1.
17 Technical dossier/Section II/Annex II.1.4.1.2.
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3.1.4. Stability and homogeneity
The shelf life of three batches of Hemicell®-L were studied at 20, 5, 25, 30 and 40°C in samples
stored in closed containers for up to 12 months (up to 3 months at 40°C). The initial mean mannanase
content was 11 9 105 Units/mL and the mean recovery of the initial enzyme activity after 3 months
was 100%, 100%, 90%, 80% and 40% for at –20, 5, 25, 30 and 40°C, respectively. The recoveries
after 12 months were 101%, 97%, 51% and 24% for samples stored at –20, 5, 25 and 30°C,
respectively.21
Three batches of the additive were sprayed onto mash or crumble feed for chickens for fattening at
an intended level of 79,200 U/kg feed (analysed activity varied from 115,000 to 150,000 U/kg feed).22
Samples of the feeds were stored in closed containers at –20, 25 and 30°C for up to 3 months and at
40°C for 1 month. Recovery values of the initial activity at the end of the study period were 100%,
90%, 80% and 77% for –20, 25, 30 and 40°C, respectively.
Ten subsamples of each batch of the feed used for the stability study were analysed after the
additive was added to study the capacity of the additive to homogeneously distribute. The CV was
below 8% in all cases.
3.1.5. Conditions of use
The additive is to be used in feed for chickens for fattening or reared for laying, turkeys for
fattening or reared for breeding and minor poultry species at the level of 79,200 U/kg feed.
3.2. Safety
3.2.1. Safety of the genetic modiﬁcation of the production strain
The production strain and its DNA were not detected in the product. The product Hemicell®-L,
manufactured with the production strain P. lentus DSM 32052, does not give rise to safety concern
with regard to the genetically modiﬁed production strain.
3.2.2. Safety for the target species
3.2.2.1. Safety for chickens for fattening
A total of 720 one day-old male chicks (Ross 708) were distributed in groups of 12 birds per pen
and allocated to three dietary treatments (20 replicates per treatment).23 During the study, three basal
diets were used according to the birds’ requirements. The three basal diets based on maize and soya
bean meal were supplemented with Hemicell®-L to provide 0, 100,000 (1.39) or 1,500,000 (199) U
mannanase/kg feed (conﬁrmed by analysis). Diets were offered in crumble/pelleted form for 35 days.
Animal health was monitored daily. Feed intake, body weight and mortality were recorded and feed to
gain ratio was calculated (on a pen basis). Necropsy was performed on animals that died during the
study. On day 35, one bird per pen was randomly chosen and blood sampled. Blood samples were
analysed for biochemical24 and haematological25 parameters. A one-way analysis of variance (ANOVA)
21 Technical dossier/Supplementary information December 2017/Annex II.4.1.3.
22 Technical dossier/Supplementary information December 2017/Annex II.4.1.4.
23 Technical dossier/Section III/Annexes III.1.1.1 and III.1.1.1.a.
24 Including albumin, albumin:globulin ratio, alkaline phosphatase, creatin phophokinase, total protein, chloride, cholesterol,
globulin, glucose, potassium, sodium, triglycerie, uric acid, alanine transaminase, aspartate aminotransferase.
25 Haematocrit, haemoglobin, white blood cells including the differential.
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was performed with the data and group means were compared with Dunnett’s test. For mortality data,
a generalised linear mixed model for binomial data was performed.
Mortality rates were 5.8%, 5.8% and 5.4% for 0, 100,000 and 1,500,000 U/kg feed, respectively,
and were not related to the treatment. Daily feed intake (g/day) was 102, 105 and 103 in the groups
fed with 0, 100,000 and 1,500,000 U/kg feed, respectively; ﬁnal body weight (g/bird) was 2,300,
2,361 and 2,355, respectively, and feed to gain ratio was 1.52,1.53 and 1.53, respectively. Blood
parameters did not signiﬁcantly differ in the different dietary groups with the exception of the basophil
counts and per cent, where the 1.39 group showed values signiﬁcantly lower than the control but no
differences were found between 199 and control; therefore, this ﬁnding is considered of no concern.
The supplementation of the experimental diets with Hemicell®-L at 199 the proposed level did not
have a negative effect on the performance of the birds.
3.2.2.2. Safety for turkeys for fattening
A total of 315 day-old male turkeys (Nicholas 85) were housed in pens with seven birds per pen
and allocated to three dietary treatments (15 replicates per treatment).26 During the 42 day study, two
basal diets (days 0–21; days 21–42) were used according to the birds’ requirements which were based
on wheat and soya bean meal. The diets were either not supplemented or supplemented with
Hemicell®-L to provide 100,000 (1.39) or 1,500,000 (199) U/kg feed (conﬁrmed by analysis). Diets
were offered in mash form for 42 days and contained monensin. Feed intake, body weight and
mortality were recorded and feed to gain ratio was calculated. Necropsy was performed on animals
that died during the study. On day 42, blood samples were collected from one bird per pen and
analysed for biochemical27 and haematological25 parameters. A one-way ANOVA was performed with
the data and group means were compared with Dunnett’s test; for mortality data, a generalised linear
mixed model for binomial data was applied.
Mortality rate was 3.8% in all groups. Daily feed intake (g/day) was 95, 92 and 97 in the control,
100,000 and 1,500,000 U/kg feed groups, respectively; ﬁnal body weight (kg bird) 2.61, 2.58 and
2.70, respectively, and feed to gain ratio was 1.58, 1.56, 1.57, respectively. In general, blood
parameters did not show signiﬁcant differences in the different dietary groups with the exception of
haemoglobin and potassium. Haemoglobin was higher in the groups receiving the mannanase
compared to control and the 100,000 U/kg group showed a higher potassium concentration compared
to the other groups. These modiﬁcations are considered of no concern. Therefore, supplementation of
the experimental diets with Hemicell®-L at up to 199 the proposed level did not have a negative
effect on the performance of the birds.
The applicant also provided another tolerance trial in turkeys for fattening performed with the
mannanase obtained from a precursor strain (holding the same mannanase gene but fewer copies).28
The data from that study showed no adverse effects after feeding turkeys the mannanase for 91 days
and up to a 100-fold the proposed level.
3.2.2.3. Conclusions on safety for the target species
Chickens for fattening and turkeys for fattening can tolerate well up to 19-fold the recommended
level of the additive. Therefore, the Panel concludes that the additive is safe at the recommended level
of 79,200 U/kg feed for chickens and turkeys for fattening. This conclusion is extended to chickens
reared for laying and turkeys reared for breeding.
Considering the margin of safety shown in the tolerance trials, the FEEDAP Panel concludes that the
additive is safe for minor poultry species for fattening or reared for laying/breeding up to the point of
lay at 79,200 U/kg feed.
3.2.3. Safety for the consumer
No studies were provided with the enzyme concentrate obtained from the production strain subject
of the current application in this application
26 Technical dossier/Supplementary information December 2017/Annex III.1.1.1.1.
27 Including albumin, albumin:globulin ratio, alkaline phosphatase, creatine phosphokinase, chloride, cholesterol, globulins,
glucose, potassium, aspartate aminotransferase, sodium total protein, triglyceride, uric acid, BUN, creatinine, total bilirubin,
alanine aminotransferase and gamma-glutamil transpeptidase.
28 Technical dossier/Section III/Annex III.1.1.1 and Supplementary information December 2017.
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comprised the following tests: a bacterial reverse mutation
assay performed in compliance with OECD Guideline 471,29,30 a chromosome aberration
test in compliance with OECD Guideline
473,31 an in vitro mammalian cell micronucleus test done with the fermentation product
in compliance with OECD Guideline 48732 and a subchronic oral toxicity study for each
strain performed according to OECD Guideline 408.33,34
The results of the genotoxicity studies showed no evidence for a genotoxicity effect of the test item
and the subchronic oral toxicity studies showed no treatment related effects in any of the parameters
evaluated.
The Panel in the present assessment evaluated if the available data could support the safety of the
product obtained with the newly proposed production strain and manufacturing process. To this scope,
three aspects were considered: the differences of the production strains, the manufacturing process
and the test items tested.
29 Technical dossier/Supplementary information December 2017/Annex III.2.2.2.3.
30 Technical dossier/Supplementary information December 2017/Annex III.2.2.2.1.1.
31 Technical dossier/Supplementary information December 2017/Annex III.2.2.2.4.
32 Technical dossier/Supplementary information December 2017/Annex III.2.2.2.2.1.
33 Technical dossier/Section III/Annex 2.2.3.
34 Technical dossier/Section III/Annex 2.2.4.
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3.2.3.1. Conclusions on safety for the consumer
Hemicell®-L obtained from the fermentation product from P. lentus DSM 32052 is considered not to
raise concerns for the consumers of food products derived from animals fed with the additive
Hemicell®-L.
3.2.4. Safety for the user
3.2.4.1. Effects on the respiratory tract
No speciﬁc studies have been provided. Enzymes are considered as potential respiratory sensitisers.
3.2.4.2. Effects on the skin and eyes
An acute dermal irritation study (OECD Guideline 404)35 and an eye irritation study (OECD
Guideline 405)36 performed in male New Zealand White albino rabbits were done with Hemicell®-L.
The results showed that the test material is non-irritant to skin or eye, respectively.
The potential of Hemicell®-L to cause or elicit skin sensitisation reactions (allergic contact
dermatitis) was assessed via the murine local lymph node assay (MLLNA), in compliance with OECD
guideline 429.37 A total of 35 female CBA/J mice were used in this study. Animals treated with
Hemicell®-L showed sensitisation index below 3 which indicates no sensitisation. The positive control
group resulted in a stimulation index of 4.6.
3.2.4.3. Conclusions on safety for the user
The additive is not a dermal or eye irritant and it is not a dermal sensitiser. However, considering
that the active substance is a protein, the additive should be regarded as a potential respiratory
sensitiser.
3.2.5. Safety for the environment
The production strain and its DNA were not detected in the ﬁnal product. The ﬁnal product does
not pose any environmental safety concern associated with the genetic modiﬁcation. The active
substance of the additive is a protein and as such it will be degraded/inactivated during passage
through the digestive tract of the animals or in the environment. Therefore, no risks to the
environment are expected and no further environmental risk assessment is required.
3.3. Efﬁcacy
The applicant submitted efﬁcacy trials in chickens and turkeys. Only one trial in turkeys for
fattening (trial 4) was conducted with the product obtained with the new production strain.
no differences would be expected regarding the efﬁcacy
of the main enzyme activity obtained with the new production strain.
35 Technical dossier/Section III/Annex III.3.1.2.1.
36 Technical dossier/Section III/Annex III.3.1.2.2.
37 Technical dossier/Section III/Annex III.3.1.2.3.
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Therefore, the studies conducted with
the product obtained following the previous manufacturing process are considered relevant for this
assessment.
3.3.1. Efﬁcacy for chickens for fattening
The efﬁcacy studies provided to support the efﬁcacy of the additive for chickens for fattening has
been evaluated in a previous opinion (EFSA, 2006). The results of the four studies showed a signiﬁcant
improvement of body weight gain in four trials and on the feed to gain ratio at the recommended level
(79,200 U/kg feed).
3.3.2. Efﬁcacy for turkeys for fattening
A total of ﬁve studies were assessed. One of the studies was not considered further due to the high
mortality registered during the study (above 10%).41
In the ﬁrst trial, a total of 480 day-old female turkeys (Nicholas) were distributed in pens in groups
of 15 birds and allocated to four dietary treatments (eight replicates per treatment).42 The birds were
offered a total of four phase diets according to the birds’ requirements. The study followed a 2 9 2
design with two basal diets and two levels of enzyme supplementation. Two treatments were obtained
from a standard basal diets (St), according to birds requirements, based on maize and soybean meal
that were either not supplemented (control) or supplemented with mannanase to provide 79,200 U/kg
feed (analytical conﬁrmation; 8,940 and 113,283 U/kg feed, respectively). The other two dietary
treatments were obtained from the standard basal diets with added dried distillers with solubles grains
(St + DDGS, 15% inclusion) that were either not supplemented (control) or supplemented with
Hemicell®-L to provide 0 or 79,200 U/kg feed (analytical conﬁrmation; 9,623 and 96,925 U/kg feed,
respectively). Diets were offered in crumb/pelleted form for 84 days.
In the second trial, two replicated studies were conducted. In each trial, an initial number of 616
day-old male turkeys (Nicholas) were distributed in pens in groups of 22 birds per pen and allocated to
four dietary treatments (seven replicates per treatment).43 The number of birds was reduced to 17 on
day 28. The studies followed a 2 9 2 design with two basal diets (with different protein and ﬁbre
content) and two levels of enzyme supplementation (0 or 100,000 U/kg feed). Two treatments were
obtained from basal diets, according to birds requirements’, based on maize and soybean meal (soya
bean meal with 48% crude protein) that were either not supplemented (control) supplemented with
Hemicell®-L to provide 100,000 U/kg feed (analytical conﬁrmation available only for the second study;
18,960 and 141,320 U/kg feed, respectively). The other two dietary treatments were obtained from
the same basal diet that was modiﬁed to include soybean meal with 44% of crude protein and soya
hulls that was either not supplemented (control) or supplemented with Hemicell®-L 100,000 U/kg feed
(analytical conﬁrmation available only for the second study; 14,990 and 145,280 U/kg feed,
respectively). Diets were offered in crumb/pelleted form for 126 days. During the study, experimental
treatments were offered in a total of ﬁve phase diet, according to the birds’ requirements.
41 Technical dossier/Section IV/Annex IV.3.3.
42 Technical dossier/Section IV/Annex IV.3.1.
43 Technical dossier/Section IV/Annex IV.3.2.
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In the third trial, a total of 760 day-old female turkeys (Nicholas) were distributed in pens in groups
of 19 birds and allocated to four dietary treatments (10 replicates per treatment).44 During the study,
the dietary treatments were offered in a total of ﬁve phase diet, according to the birds’ requirements.
The studies followed a 2 9 2 design with two basal diets with two different energy contents and two
levels of enzyme supplementation (0 or 79,200 U/kg). Two treatments were obtained from basal diets
(from starter to ﬁnisher) containing a very low energy content (VLEC, 11.85–13.85 MJ ME/kg feed)
that was either not supplemented (control) or supplemented with Hemicell®-L to provide 79,200 U/kg
feed (conﬁrmation: 10,800 and 120,560 U/kg feed). The other two dietary treatments were obtained
from a diet formulated to contain 0.25 MJ ME/kg feed more compared to VLEC, low energy content
(LEC) that was either not supplemented (control) or supplemented with Hemicell®-L 79,200 U/kg feed
(conﬁrmation: 12,800 and 120,640 U/kg feed). Diets were offered in mash/pelleted form for 98 days.
In the fourth trial, a total of 480 day-old female turkeys (BUT10) were distributed in pens in groups
of 20 birds and pens were allocated to two dietary treatments (representing 12 replicates per
treatment).45 During the study, the dietary treatments were offered in a total of ﬁve phase diet,
according to the birds’ requirements. The basal diets were either not supplemented (control) or
supplemented with Hemicell®-L to provide 100,000 U/kg feed (conﬁrmation below limit of
quantiﬁcation (LOQ) and 130,000 U/kg feed). Feed was offered in pelleted form during 3 weeks, later
on it was offered in crumbles up to week 12 of life.
During the studies, mortality and general health of the birds was monitored. Feed intake and body
weight of the birds were measured throughout the study and feed to gain was calculated.
An ANOVA was done with the data from each study, separately. The experimental units were the pens.
The model used included the treatment in all trials; in trial 2, the study, the basal diet, the enzyme and
their interactions were considered. Mean groups were compared using the Tukey test. The results of the
studies are presented in Table 1.
Mortality in the trials was not different between the treatments. In trial 1, the birds receiving the
enzyme at the recommended level in a standard diet showed a better feed to gain ratio compared to
Table 1: Effect of Hemicell®-L on the performance of turkeys for fattening
Trial Basal diet
Intended
level
(U/kg)
Feed intake
(kg)1
Body weight2
(kg)
Feed to gain
ratio
Mortality
(%)
13 St 0 16.86a 7.72ab 2.19b 4.17
St 79,200 16.12ab 7.89a 2.04a 0.83
St + DDGS 0 16.52ab 7.51b 2.20b 1.67
St + DDGS 79,200 15.66b 7.56b 2.07ab 0.83
24 SBM 48 0 41.65 14.91 2.70 8.08
SBM 48 100,000 41.00 15.03 2.63 5.06
SBM 44 0 41.81 14.39 2.79 2.88
SBM 44 100,000 41.25 14.77 2.70 4.74
35 LEC 0 20.25b 9.24b 2.17ab 2.1
LEC 79,200 20.52ab 9.56a 2.13b 1.6
VLEC 0 20.38b 9.18b 2.21a 1.1
VLEC 79,200 21.11a 9.55a 2.19a 2.1
4 – 0 0.209 8.02 2.20a 0
– 100,000 0.204 8.05 2.15b 1.25
1 Values are total feed intake in trials 1, 2 and 3, and daily feed intake in trial 4.
2 Values are body weight gain in trials 1 and 3, and body weight in trials 2 and 4.
3 St: maize and soybean meal-based diet, St + DDGS: St + 15% dried distillers grain with solubles
4 SBM 48: soya bean meal crude protein 48% and maize diet, SBM 44: soya bean meal crude protein 44% and maize diet.
The diets with SBM 48 showed higher values of protein and lower values of ﬁbre compared to the SBM 44%. The mean values
for the effect of the enzyme are not provided in the report.
5 VLEC: very low energy content diet formulated to have 11.85–13.85 MJ/kg feed from starter to ﬁnisher diets; LEC: low energy
content diet formulated to have 0.25 MJ/kg feed more than VLEC in each phase.
a,b, values within a column and within a study with different superscript are signiﬁcantly different (p < 0.05).
44 Technical dossier/Section IV/Annex IV.3.4.
45 Technical dossier/Supplementary information December 2017/Annex IV.3.5.
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control. In trial 2, the results showed no interactions between the basal diet and the addition of the
enzyme. The birds receiving the enzyme at 100,000 U/kg feed, regardless of the basal diet, showed
signiﬁcantly lower feed intake, higher body weight and consequently a better feed to gain ratio. In
trial 3, birds receiving the enzyme at the recommended level showed a higher body weight, regardless
of the basal diet considered. In trial 4, birds receiving the enzyme at 100,000 U/kg feed showed a
better feed to gain ratio.
The Panel notes that the data provided with turkeys for fattening would support the efﬁcacy at
100,000 U/kg feed. However, considering the provisions of the Guidance on the assessment of efﬁcacy
for feed additive (EFSA FEEDAP Panel, 2017), the Panel would extrapolate the efﬁcacious level in
chickens for fattening (79,200 U/kg feed) to turkeys for fattening.
3.3.2.1. Conclusions on efﬁcacy for the target species
The Panel concludes that the additive has potential to be efﬁcacious as a zootechnical additive in
chickens for fattening and turkeys for fattening at 79,200 U/kg feed. The Panel considers that these
conclusions apply to chickens reared for laying and turkeys reared for breeding at the corresponding
levels.
The effect of the additive can reasonably be expected to be the same among poultry species.
Therefore, the Panel considers that the conclusions reached in chickens for fattening can be
extrapolated to all minor poultry species for growing or reared for laying/breeding purposes.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation46 and Good
Manufacturing Practice.
4. Conclusions
Viable cells and the DNA of the production strain were not found in the intermediate product used
to formulate the additive. The product Hemicell®-L, manufactured with the production strain P. lentus
DSM 32052, does not give rise to safety concern with regard to the genetically modiﬁed production
strain.
The additive is safe at the recommended level for chickens and turkeys for fattening. This
conclusion is extended to chickens reared for laying and turkeys reared for breeding and extrapolated
to minor poultry species for growing or reared for laying/breeding purposes.
The additive obtained from P. lentus DSM 32052 raises no safety concerns for the consumer of food
products derived from animals receiving the additive.
The additive is not a dermal or eye irritant and it is not a dermal sensitiser. However, considering
that the active substance is a protein, the additive should be regarded as a potential respiratory
sensitiser.
The use of the product as a feed additive raises no concerns for the environment.
The additive has a potential to be efﬁcacious as a zootechnical additive in chickens for fattening or
reared for laying, turkeys for fattening and reared for breeding purposes, minor poultry species for
growing or reared for laying/breeding purposes at 79,200 U/kg.
Documentation provided to EFSA
1) Hemicell®-L for chickens. December 2015. Submitted by Eli Lilly and Company Ltd.
2) Hemicell®-L for turkeys. December 2015. Submitted by Eli Lilly and Company Ltd.
3) Hemicell®-L for chickens. Supplementary information. December 2017. Submitted by Eli Lilly
and Company Ltd.
4) Hemicell®-L for turkeys. Supplementary information. December 2017. Submitted by Eli Lilly
and Company Ltd.
5) Comments from Member States.
46 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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Chronology
Date Event
26/11/2015 FAD-2015-0042 Dossier received by EFSA
21/12/2015 FAD-2015-0047 Dossier received by EFSA
11/12/2015 FAD-2015-0042 Reception mandate from the European Commission
19/01/2016 FAD-2015-0047 Reception mandate from the European Commission
14/04/2016 Applications validated by EFSA – Start of the scientiﬁc assessment
09/06/2016 FAD-2015-0047 Request of supplementary information to the applicant in line with Article 8(1)(2)
of Regulation (EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation,
safety
13/06/2016 FAD-2015-0042 Request of supplementary information to the applicant in line with Article 8(1)(2)
of Regulation (EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: characterisation,
safety
14/07/2016 Comments received from Member States for the two applications
21/12/2017 Reception of supplementary information from the applicant for the two applications - Scientiﬁc
assessment re-started
26/04/2018 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 for the two applications – Scientiﬁc assessment suspended Issues: efﬁcacy
24/01/2019 Reception of supplementary information from the applicant for the two applications - Scientiﬁc
assessment re-started
26/02/2019 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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ATCC American Type Culture Collection
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CV coefﬁcient of variation
DSMZ German Collection of Microorganisms and Cell Cultures
EURL European Union Reference Laboratory
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
LEC low energy content
LOQ limit of quantiﬁcation
MLLNA murine local lymph node assay
OECD Organisation for Economic Co-operation and Development
PCDD polychlorinated dibenzo-p-dioxins
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PCR polymerase chain reaction
TEQ toxic equivalent
VLEC very low energy content
WHO World Health Organization
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